All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
CAR T-cell therapy: how can we improve toxicity management
Bookmark this article
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub was pleased to speak to Jordan Gauthier, Fred Hutchinson Cancer Research Center, Seattle, US. We asked: How can we improve toxicity management in patients receiving CAR T-cell therapy for acute lymphoblastic leukemia (ALL)?
CAR T-cell therapy: how can we improve toxicity management
Jordan Gauthier gives a detailed discussion on the current and investigational approaches for the prevention and management of main toxicities related to CAR T-cell therapy, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).
More about...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox